Blog

Advancing pharmacoequity through model-informed drug development: Insights from ASCPT 2026

Explore how model-informed drug development and AI are advancing pharmacoequity and shaping the future of…

CertaraMarch 11, 2026

Webinar

What is new in Phoenix 8.8?

Danielle PillsburyMarch 9, 2026

Webinar

Modeling Platinum-Induced Nephrotoxicity: A PK/TD Analysis of Calbindin and B2-Microglobulin Urinary Biomarkers

CertaraMarch 9, 2026

Guide

Navigate GxP Compliance in the Cloud with Confidence

Master SaaS GxP compliance with risk-based computer system validation (CSV) aligned to GAMP 5, FDA,…

CertaraMarch 6, 2026

Blog

ADC First-in-Human (FIH) Dose Selection: Designing FIH Studies for Success

Optimize ADC First-in-Human Dose Selection with model-informed strategies and exposure–response insights to design safer, more…

CertaraMarch 3, 2026

Conference

Apotekarsocieteten Clinical Pharmacology Strategies in Drug Development

Danielle PillsburyMarch 2, 2026

Live Events

Phoenix Roadshow 2026 – Cambridge

CertaraMarch 2, 2026

On-Demand Webinar

Formulate Faster: A Purpose-Built Toolkit for Bioequivalence (Phoenix IVIVC Toolkit)

This webinar introduces the Phoenix IVIVC Toolkit, showing how to perform BE analysis and build…

CertaraFebruary 27, 2026

Blog

Rare Disease Day 2026: Accelerating Rare Disease Drug Development Through Cross-Functional Innovation

On Rare Disease Day 2026, Certara experts share how cross-functional innovation, regulatory strategies for rare…

CertaraFebruary 26, 2026

Webinar

Maximizing the Impact of Antibody–Drug Conjugates (ADCs): Model-Informed Labeling, Expansion, and Market Access

Danielle PillsburyFebruary 23, 2026

Clinical Pharmacology

Advancing pharmacoequity through model-informed drug development: Insights from ASCPT 2026

What is new in Phoenix 8.8?

Modeling Platinum-Induced Nephrotoxicity: A PK/TD Analysis of Calbindin and B2-Microglobulin Urinary Biomarkers

Navigate GxP Compliance in the Cloud with Confidence

ADC First-in-Human (FIH) Dose Selection: Designing FIH Studies for Success

Apotekarsocieteten Clinical Pharmacology Strategies in Drug Development

Phoenix Roadshow 2026 – Cambridge

Formulate Faster: A Purpose-Built Toolkit for Bioequivalence (Phoenix IVIVC Toolkit)

Rare Disease Day 2026: Accelerating Rare Disease Drug Development Through Cross-Functional Innovation

Maximizing the Impact of Antibody–Drug Conjugates (ADCs): Model-Informed Labeling, Expansion, and Market Access

Newsletter sign up

Quick links

Solutions

Contact